Fatal cases of gabexate mesilate-induced anaphylaxis.

Abstract

Gabexate mesilate, ethyl-4-(6-guanidinohexanoyloxy) benzoate monomethanesulfonate (C16H23N3 O4CH4O3S: M.W. 417.48), is a synthetic protease inhibitor and was introduced for clinical use in 1978. It rarely induces anaphylaxis, and patients with gabexate mesilate-induced shock had been reported to survive with appropriate treatments including respiratory support. However, there were increasing reports on fatal cases in recent years: 6 cases have been reported to develop fatal anaphylaxis following dripping infusions of gabexate mesilate. All the fatal cases rapidly developed anaphylaxis (within 5 minutes), whereas 7 out of 11 in recovered cases developed it 5 or more minutes after the injection. Venous access should be kept for at least 30 minutes to prepare for and to treat this fatal reaction in patients receiving gabexate mesilate repeatedly.

• Authors: Y Matsukawa, S Nishinarita, S Sawada, T Horie
• Journal: International journal of clinical pharmacology research (Int J Clin Pharmacol Res) Vol. 22 Issue 3-4 Pg. 81-3 ( 2002) ISSN: 0251-1649 [Print] Switzerland
• PMID: 12837044 (Publication Type: Case Reports, Journal Article)

Chemical References

• Serine Proteinase Inhibitors
• Gabexate

Topics

• Anaphylaxis (chemically induced)
• Fatal Outcome
• Female
• Gabexate (adverse effects)
• Humans
• Male
• Middle Aged
• Pancreatitis (prevention & control)
• Serine Proteinase Inhibitors (adverse effects)